Maximizing impact of biosimilar meds requires strategic action in Europe

A surge in biologics losing market exclusivity creates an opportunity to increase access to treatment, free up vital healthcare resources, enhance budget sustainability thanks to effective market competition. The latest research underscores critical challenges that must be addressed to unlock the potential of this important segment of the European biotech industry.

The 2024 IQVIA report, “The Impact of Biosimilar Competition in Europe,” highlights a dynamic market shaped by competition but also hindered by structural gaps. These findings, presented at the European Commission’s annual biosimilar stakeholder event, provide an important reflection point for the future of European and national biosimilar medicines strategies.

Gaps recorded in the biosimilar pipeline, first identified in the 2022 edition of the report, continue to raise concerns as to the ability for Europe to sustain biosimilar benefits without targeted policy and investment efforts.